Bristol-Myers Squibb GmbH & Co.KG aA

New Data on Four Bristol-Myers Squibb Compounds to be Presented at AASLD 2009

    Princeton, New Jersey (ots/PRNewswire) -

    New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

    Data will be presented on BARACLUDE(R) (entecavir) in patients with chronic hepatitis B, and on two compounds in early clinical development for the treatment of hepatitis C -- BMS-650032, an NS3 inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The presentation of data on BMS-650032 will mark the first public disclosure of information about this investigational compound. Data will also be presented on the investigational compound brivanib, the first selective dual inhibitor of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) signaling, which is in Phase 3 development for the treatment of hepatocellular carcinoma.

    "The data on Bristol-Myers Squibb compounds that will be presented at AASLD demonstrate the breadth of our research and development portfolio and support the company's goal of developing innovative medicines for patients with various diseases of the liver," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "Our established expertise in viral hepatitis and oncology uniquely position Bristol-Myers Squibb to be at the forefront of delivering innovation in the treatment of multiple types and stages of liver disease. We are proud to be releasing new data on our significant portfolio of assets."

    BARACLUDE, BMS-650032 and brivanib were discovered by Bristol-Myers Squibb Research and Development. BMS-650032 is Bristol-Myers Squibb's second small molecule under development for the treatment of hepatitis C, joining BMS-790052, a first-in-class investigational NS5A inhibitor of the hepatitis C virus.

    PEG-Interferon lambda was discovered by ZymoGenetics, Inc. Bristol-Myers Squibb and ZymoGenetics announced a global collaboration for PEG-Interferon lambda and its related development program earlier this year.

    The times, titles and lead authors of the data presentations are as follows:

      Date/Time          Presentation Title            Lead Author
      ---------          ------------------            -----------
      Hepatitis B
      October 31,        Efficacy and Safety of      Y. Liaw
      2:00 - 8:00        Entecavir versus                Chang Gung
      p.m. EDT            Adefovir in Chronic          Memorial Hospital,
                                Hepatitis B Patients         Chang Gung
                                with Evidence of                University
                                Hepatic                              College of Medicine
                                Decompensation                  Taipei, Taiwan
                                (Abstract #422)
      Hepatitis C
      November 3,        Safety, Tolerability,        C. Pasquinelli
      12:00 - 12:15    Pharmacokinetics and         Bristol-Myers Squibb
      p.m. EST            Antiviral Activity
                                following Single- and
                                Multiple-Dose
                                Administration of
                                BMS-650032, a Novel
                                HCV NS3 Inhibitor, in
                                Subjects with Chronic
                                Genotype 1 HCV
                                Infection (Abstract
                                #225)
      November  3,      Genotypic and                    F. McPhee
      8:00 a.m. -        Phenotypic Analysis          Bristol-Myers Squibb
      1:00 p.m. EST    of Samples from
                                HCV-Infected Subjects
                                Treated with
                                BMS-650032 in a
                                Single Ascending Dose
                                Study (Abstract #1607)
      November 3,        A Phase 1b                         A.J. Muir
      8:00 a.m. -        Dose-Ranging Study of        Duke University
      1:00 p.m. EST    4 Weeks of                         School of Medicine
                                PEG-Interferon (IFN)         Durham, North Carolina
                                Lambda (PEG-rIL-29)
                                in Combination with
                                Ribavirin (RBV) in
                                Patients with Chronic
                                Genotype 1 Hepatitis
                                C Virus (HCV)
                                Infection (Abstract
                                #1591)
      Hepatocellular Carcinoma
      November 3,        Time-to-Progression          R. Finn
      8:00 a.m. -        Analysis of                        UCLA Los Angeles, CA
      1:00 p.m. EST    Second-line Treatment
                                with Brivanib in
                                Patients with
                                Unresectable, Locally
                                Advanced, or
                                Metastatic
                                Hepatocellular
                                Carcinoma (Abstract
                                #1683)
      November 3,        Cell-dependent                  J. Park
      8:00 a.m. -        Response of                        National Cancer Center
      1:00 p.m. EST    BMS-582664 (Brivanib)        Goyang, South Korea
                                in Hepatocellular
                                Carcinoma Cells: Gene
                                Expression Profiling
                                Study (Abstract #1668)

    About BARACLUDE(R)

    Discovered at Bristol-Myers Squibb, BARACLUDE(R) is a nucleoside analogue indicated for use in adults with chronic hepatitis B infection with compensated liver disease, evidence of active viral replication, and either evidence of persistent elevations of the blood levels of aminotransferases - a marker for liver disease - or active liver disease as determined by biopsy. BARACLUDE (entecavir) has been approved in more than 86 countries and regions around the world.

    About Bristol-Myers Squibb

    Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

    BARACLUDE(R) (entecavir) is a registered trademark of Bristol-Myers Squibb Company.

ots Originaltext: Bristol-Myers Squibb GmbH & Co.KG aA
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Media, Annie Simond, office: +33-1-58-83-65-66, annie.simond@bms.com,
or Investors, John Elicker, +1-609-252-4611, john.elicker@bms.com



Das könnte Sie auch interessieren: